Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating.
The company reported earnings per share of $8.02, exceeding the projected $5.95. Revenue also came in slightly above expectations, totaling $1.29 billion vs $1.28 billion.
According to Oppenheimer, Vyvgart’s total revenues for the fourth quarter of 2025 totaled $1.29 billion, a 74% increase over the previous year. Vyvgart’s crucial myositis readout in the third quarter may pave the path for an additional 20,000-patient opportunity.
Additionally, on February 26, BofA Securities maintained a Buy rating on Argenx SE and increased its price objective from $1,006 to $1,013. The firm ranked Argenx as a top pick and kept its Vyvgart sales projection flat compared to the fourth quarter of 2025 for the coming first-quarter 2026 earnings.
Argenx SE is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
